INVO Fertility (NASDAQ:IVF) Issues Quarterly Earnings Results

INVO Fertility (NASDAQ:IVF) posted its quarterly earnings data on Tuesday. The company reported $472.78 earnings per share for the quarter, FiscalAI reports. The firm had revenue of $1.60 million for the quarter.

INVO Fertility Price Performance

INVO Fertility stock opened at $1.70 on Thursday. The firm has a market cap of $2.75 million, a price-to-earnings ratio of 0.00 and a beta of 2.33. INVO Fertility has a fifty-two week low of $1.38 and a fifty-two week high of $192.00. The firm has a fifty day moving average price of $2.02 and a two-hundred day moving average price of $4.91.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in INVO Fertility stock. Armistice Capital LLC bought a new position in shares of INVO Fertility, Inc (NASDAQ:IVF) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 207,644 shares of the company’s stock, valued at approximately $156,000. Armistice Capital LLC owned about 8.69% of INVO Fertility at the end of the most recent reporting period. 12.02% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Wall Street Zen raised shares of INVO Fertility from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Maxim Group set a $20.00 price objective on shares of INVO Fertility in a research note on Tuesday, February 10th. Finally, Weiss Ratings raised shares of INVO Fertility from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $20.00.

About INVO Fertility

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.